AEON Biopharma posts corporate presentation with biosimilar pipeline update

AEON Biopharma, Inc.

Presentation dated December 2025 highlights fresh data and new capital for full-label biosimilar approval.
Company emphasizes simplified structure to accelerate development of lead molecule.
No specific clinical or financial figures were disclosed in the furnished presentation excerpt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.